Kadcyla FDA Proprietary Name Review
Kadcyla proprietary name review
Nonclinical safety evaluation of immunoconjuates Melissa M Schutten, D Antibody-Drug Conjugates: Modes of Toxicity Melissa M. Schutten, DVM, PhD, DACVP.
Updates in the Treatment of Breast cancer Mohammad Jahanzeb, MD, FACP Professor of Clinical Medicine, Hematology-Oncology Director, UM Sylvester Deerfield.
New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive.
AUGUST 2012 I VOL 5, NO 5 I SPECIAL ISSUE
